Therapy Areas: AIDS & HIV
Aimmune Therapeutics Nets USD 164m in Public Offering of Common Stock
5 March 2018 - - Brisbane, California-based food allergy treatment developer Aimmune Therapeutics, Inc. (NASDAQ: AIMT) has completed its previously announced underwritten public offering of 5.5m shares of its common stock at a price to the public of USD 32.00 per share, the company said.
All shares in the offering were sold by Aimmune, with gross proceeds to Aimmune of USD 176m and net proceeds of approximately USD 164.2m, after deducting underwriting discounts and commissions and estimated offering expenses.
In addition, Aimmune has granted the underwriters of the offering a 30-day option to purchase up to an additional 825,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
Aimmune Therapeutics is developing treatments for life-threatening food allergies. The company's Characterized Oral Desensitization ImmunoTherapy (CODIT) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens.


Related Headlines